hotspot -WSS

hotspot

author：focus 2025-09-03 15:19:02 - browse：1863

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： Medical records are filled with copy
Next article： The United States is paying nearly triple for new Covid vaccines

entertainment

explore

WSS

6 solutions to address cancer drug shortages and others

RSV injection headlines need to be accurate for good uptake

Some top drug companies are starting to take action on climate

WHO recommends second malaria vaccine

Congress extends some pandemic preparedness programs

What will Novo Nordisk's VC do with its influx of cash?

entertainment

hotspot

focus

Medical records are filled with copy

WHO recommends second malaria vaccine

Medical leaders decry Supreme Court decision on affirmative action

IVG is promising — but it won’t replace IVF quite yet

Malaria cases in Florida and Texas: Here’s what you need to know

Why rehabilitation engineers need to center patients in their research

How one medical school became remarkably diverse

Key Senate committee drafts bipartisan bill to stem drug shortages

The high cost of giving birth even with insurance

Experts study whether long Covid risk adds up with each reinfection

knowledge

Flu, Covid vaccination rates decline, new survey data show

WHO recommends second malaria vaccine

Study points to new risk in gene therapy death of Terry Horgan

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Health insurers' Q3 question: how much care are people getting?

Q&A: Jennifer Adair on making gene therapy available globally

entertainment

explore

entertainment

focus